Cargando…

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms

BACKGROUND: In men aged above 50 yr, lower urinary tract symptoms (LUTS), benign prostate hyperplasia, and prostate cancer are common urological conditions. Current guidelines for general practitioners frequently recommend prostate-specific antigen (PSA) testing in patients with LUTS for the detecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nordström, Tobias, Engel, Jan Chandra, Bergman, Martin, Egevad, Lars, Aly, Markus, Eklund, Martin, Palsdottir, Thorgerdur, Grönberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317798/ https://www.ncbi.nlm.nih.gov/pubmed/34337490 http://dx.doi.org/10.1016/j.euros.2020.12.004

Ejemplares similares

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
por: Waldén, Mauritz, et al.
Publicado: (2022)

Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
por: Tosoian, Jeffrey J., et al.
Publicado: (2021)

Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
por: Gongora, Magdalena, et al.
Publicado: (2022)

Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths
por: Lycken, Magdalena, et al.
Publicado: (2022)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
por: Guldvik, Ingrid J., et al.
Publicado: (2020)

Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy
por: Blow, Tahj A., et al.
Publicado: (2023)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Which Type of Exercise During Radiation Therapy Is Optimal to Improve Fatigue and Quality of Life in Men with Prostate Cancer? A Bayesian Network Analysis
por: Xiong, Xingyu, et al.
Publicado: (2022)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Clinical Value of a Routine Urine Culture Prior to Transrectal Prostate Biopsy
por: Örtegren, Joakim, et al.
Publicado: (2022)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Surgeon Automated Performance Metrics as Predictors of Early Urinary Continence Recovery After Robotic Radical Prostatectomy—A Prospective Bi-institutional Study
por: Hung, Andrew J., et al.
Publicado: (2021)

Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
por: Orabi, Hazem, et al.
Publicado: (2022)

The Efficacy of Cyclooxygenase-2 Inhibitors for the Male Treatment of Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis
por: Tang, Gonglin, et al.
Publicado: (2023)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
por: Mehra, Niven, et al.
Publicado: (2023)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
por: Woo, Henry H., et al.
Publicado: (2022)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
por: Chai, Yumeng, et al.
Publicado: (2021)

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study
por: Wei, Yongbao, et al.
Publicado: (2022)

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters
por: Kang, Hyunseon C., et al.
Publicado: (2021)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Role of the Prostate Imaging Quality PI-QUAL Score for Prostate Magnetic Resonance Image Quality in Pathological Upstaging After Radical Prostatectomy: A Multicentre European Study
por: Windisch, Olivier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sspj1a4ur24cq4j7ffqooheh5h